David Callanan, MD
Enriched profileSenior Vice President & Chief Medical Officer, Aviceda Therapeutics · Aviceda Therapeutics
David Callanan is Senior Vice President & Chief Medical Officer, Aviceda Therapeutics at Aviceda Therapeutics. OpenAlex indexes 119 publications with 5,919 citations (h-index 39); ClinicalTrials.gov lists 5 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
David Callanan, MD, is Senior Vice President & Chief Medical Officer, Aviceda Therapeutics. The public record shows 119 publications with 5,919 citations (h-index 39), centered on Macular Degeneration (AMD), Dry Eye / Uveitis, Glaucoma. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 5 companies, 1 NIH-funded awards (1985–1986).
- Most recent indexed publication: 2026 · Journal of vitreoretinal diseases
- Top research focus: Macular Degeneration (AMD)
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 2 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema
Sponsor: Aviceda Therapeutics, Inc.
- A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Sponsor: Aviceda Therapeutics, Inc.
- A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)
Sponsor: Johns Hopkins University
Industry payments
Updated 27 Aug 2026
5 companies reported payments to CMS in program years 2021–2022. These are public disclosures, not judgments. The latest:
- EyePoint Pharmaceuticals US, Inc.Program year20223 payments
- Genentech USA, Inc.Program year20221 payment
- Alimera Sciences, Inc.Program year20212 payments
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
54.2%Corticosteroid54.2%Prednisolone Acetate100%Part D<11 patientsAnti-infectives
45.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor45.8%Valacyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 1985–1986 per NIH RePORTER. The latest:
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Multifocal Electroretinography Outcomes Following AVD-104 Treatment for Geographic Atrophy.
Journal of vitreoretinal diseases
Article2026 - Impact of Modifying Abicipar Manufacturing Process in Patients with Neovascular Age-Related Macular Degeneration: MAPLE Study Results.
Clinical ophthalmology (Auckland, N.Z.)
Clinical Trial2023
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/david-callanan-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/david-callanan-82512aa
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
asrs.org/find-a-specialist/profile/140/David-Callanan
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asrs.org ↗
Mentions by others
where others cite or feature them- Other
businesswire.com/news/home/20210111005213/en/Aviceda-Therapeutics-Announces-Formation-of-Executive-Team
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →businesswire.com ↗ - Other
texasretina.com/our-physicians/david-callanan-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasretina.com ↗ - LinkedIn
LinkedIn profile listing him as CMO at Aviceda Therapeutics (auth-walled; title corroborated via SERP snippet)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Iowa College of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →avicedarx.com ↗ - Residency
Internal Medicine and Ophthalmology, Parkland Memorial Hospital / UT Southwestern
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →avicedarx.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →avicedarx.com ↗
- Board Certified
American Board of Ophthalmology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Editorial & leadership roles
journal and society appointments- Elected Member
The Macula Society
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →avicedarx.com ↗ - Elected Member
Club Jules Gonin
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →avicedarx.com ↗ - Member
American Academy of Ophthalmology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →avicedarx.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →avicedarx.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →texasretina.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →avicedarx.com ↗
Secondary affiliations
appointments beyond the home institution- Clinical Professor
Department of Ophthalmology, UT Southwestern Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →avicedarx.com ↗ - Board of Directors
Retina Foundation of the Southwest
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →avicedarx.com ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →businesswire.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →modernretina.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore